2025 SITC Election | Vice President | At-Large Directors
The 2025 SITC Election will take place May 2–16, 2025. SITC regular or emertius members eligible to vote and help choose the future leaders of the society.
Related Articles
Surgical Outcomes with Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
In AEGEAN, perioperative durvalumab plus neoadjuvant chemotherapy, versus neoadjuvant chemotherapy alone, significantly improved event-free survival and pathological complete response (primary endpoints; modified ITT [mITT] population,…
Advances in Cancer Immunotherapy: A Focus on Cellular Therapies, T Cell Engagers and TIL Therapies
Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of cellular therapies, T Cell Engagers and TIL Therapies
Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer
Most of the published data with trastuzumab deruxtecan (T-DXd) derive from clinical trials with selected populations and little representation of US patients. Limited real-world data…
Global trends in lung cancer incidence and mortality by age, gender and morphology and forecast: A bootstrap-based analysis
Lung cancer (LC) incidence and mortality have changed significantly over the past few decades, yet the disease remains the leading cause of cancer-related deaths worldwide.…
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
Sugemalimab with chemotherapy showed a superior long-term overall survival benefit compared with placebo with chemotherapy, as a first-line treatment for patients with NSCLC with no…
Genomic landscape of resected invasive mucinous adenocarcinoma of the lung
Invasive mucinous adenocarcinoma (IMA) is a type of primary lung adenocarcinoma characterized by tumor cells that exhibit a goblet or columnar cell morphology and contain…
CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC
Canakinumab is a human monoclonal anti–interleukin-1β antibody with the potential to enhance the activity of PD-(L)1 inhibitors by inhibiting protumor inflammation.
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC‒A Brief Report
The PHAROS primary analysis showed robust antitumor activity and acceptable safety with encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report…
Welcome! You are invited to join a webinar: Post-ASCO 2025 Lung Cancer Highlights. After registering, you will receive a confirmation email about joining the webinar.
Virtual webinar featuring presentations & discussions on selected abstracts in lung cancer from ASCO 2025. Chaired by Noemí Reguart Moderated by Stephen Liu, Nicolas Girard…
Osimertinib as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting: updated overall survival data (OSI-FACT-OS)
Microabstract: Osimertinib showed PFS of 20.1 months and OS of 42.0 months in EGFRm+ NSCLC, comparable to those of the FLAURA trial. Adverse events included…